GILD 10-Q Quarterly Reports

Gilead Sciences, Inc. reported solid financial results for the third quarter and first nine months of 2025, demonstrating revenue growth and a significant turnaround in profitability compared to the prior year. Total revenues for the third quarter of 2025 increased by 3% year-over-year to $7.8 billion, driven by strong performance in the HIV and Liver Disease segments, alongside a notable surge in royalty, contract, and other revenues. For the first nine months, total revenues grew 2% to $21.5 billion. The company achieved substantial net income of $3.1 billion for the quarter and $6.3 billion for the nine-month period, a significant improvement from the net loss reported in the comparable periods of 2024. This profitability boost was largely attributed to the absence of substantial impairment charges seen in the prior year, coupled with increased royalty income and lower acquired R&D expenses. Diluted earnings per share also saw a strong recovery, reflecting these improved financial outcomes.

Gilead Sciences, Inc. reported solid financial performance for the second quarter of fiscal year 2025, with total revenues reaching $7.08 billion, a 2% increase year-over-year. This growth was primarily driven by strong performance in the HIV segment, particularly from Biktarvy and Descovy sales, which saw significant increases. The company also experienced growth in Trodelvy sales within its Oncology segment. Net income attributable to Gilead surged by 21% to $1.96 billion, with diluted earnings per share rising to $1.56. This improvement was bolstered by higher product sales and a favorable swing in unrealized gains on equity securities compared to the prior year. However, the company did incur a $190 million impairment charge related to its bulevirtide IPR&D intangible asset due to increased market competition. Despite this, Gilead's robust product sales, particularly in HIV, and a more favorable equity investment performance contributed to a strong quarter.

Gilead Sciences, Inc. reported a net income of $1.3 billion for the first quarter of 2025, a significant recovery from the $4.2 billion net loss in the prior year's quarter. This turnaround was largely driven by the absence of a substantial $3.9 billion acquired in-process R&D expense related to the CymaBay acquisition and a $2.4 billion IPR&D impairment charge recorded in Q1 2024, both of which did not recur. Total revenues remained stable at $6.7 billion, with a slight decrease of 1% in product sales, which was mitigated by an increase in royalty, contract, and other revenues. Key drivers of revenue performance included a 6% increase in HIV product sales, primarily from Biktarvy, and a 3% rise in Liver Disease products, boosted by the launch of Livdelzi. Conversely, Veklury sales saw a sharp decline of 45% due to lower COVID-19 related hospitalizations. Oncology sales experienced a slight decrease. The company continues to focus on its strategic priorities, including investing in its R&D pipeline and business development, while demonstrating a strong liquidity position with $7.9 billion in cash and cash equivalents as of March 31, 2025.

Gilead Sciences, Inc. reported strong revenue growth in the third quarter of 2024, with total revenues reaching $7.5 billion, a 7% increase year-over-year, driven primarily by robust performance in its HIV segment. This growth was partially offset by significant non-cash charges, including an $1.8 billion impairment related to the Trodelvy NSCLC IPR&D asset and higher acquired IPR&D expenses, which resulted in a net loss of $1.3 billion for the nine-month period. Despite the net loss, the company demonstrated positive operating cash flow, highlighting the underlying strength of its commercial operations and the ongoing demand for its key products. The company continues to strategically invest in its pipeline and expand its portfolio through acquisitions and collaborations. Notable developments include the FDA's accelerated approval of Livdelzi for primary biliary cholangitis and positive Phase 3 data for lenacapavir in HIV prevention, positioning Gilead for future growth. However, the company faces ongoing legal challenges and potential patent expirations, which remain key areas for investor attention.

Gilead Sciences, Inc. (GILD) reported $6.95 billion in total revenues for the second quarter of 2024, a 5% increase compared to the same period last year. This growth was primarily driven by strong performance in HIV, Oncology, and Liver Disease segments. Diluted earnings per share (EPS) for the quarter were $1.29, a significant increase from $0.83 in Q2 2023, reflecting improved revenues and lower operating expenses. Despite a strong Q2 performance, the six-month period ending June 30, 2024, showed a net loss of $2.56 billion. This was largely attributable to a significant acquired in-process R&D charge of $3.9 billion related to the CymaBay acquisition and a $2.4 billion impairment charge on IPR&D assets for Trodelvy's NSCLC indication. The company also reported a decrease in cash and cash equivalents, primarily due to the CymaBay acquisition and dividend payments. Gilead's balance sheet remains robust, but investors should monitor the impact of significant R&D charges and ongoing litigation.

Gilead Sciences, Inc. reported a net loss of $4.17 billion for the first quarter of 2024, a significant decrease from a net income of $1.01 billion in the prior year period. This loss was largely attributed to a substantial acquired in-process research and development (IPR&D) charge of $3.9 billion related to the acquisition of CymaBay Therapeutics and a $2.4 billion impairment charge for certain IPR&D assets connected to Trodelvy. Despite the net loss, total revenues saw a 5% increase year-over-year, reaching $6.69 billion. This growth was driven by strong performance in HIV and Oncology segments, with notable increases in Biktarvy and Trodelvy sales. However, Veklury sales experienced a decline, reflecting decreased COVID-19 related hospitalizations. Financial activities during the quarter included significant investments in acquisitions, notably the CymaBay purchase, and ongoing share repurchases and dividend payments, contributing to a decrease in cash and cash equivalents.

Gilead Sciences, Inc. reported steady revenues for the third quarter and the first nine months of 2023, with total revenues reaching $7.05 billion and $20.0 billion, respectively, showing a slight increase of 1% year-over-year for the nine-month period. Net income attributable to Gilead saw significant growth, up 22% to $2.18 billion for the quarter and 44% to $4.24 billion for the nine months, driven by increased product sales in Oncology and HIV, along with a favorable year-over-year comparison due to the absence of a large IPR&D impairment charge recognized in the prior year. Product sales within the HIV segment demonstrated robust growth, particularly Biktarvy, contributing to a 4% increase in HIV product sales for the quarter. The Oncology segment also performed strongly, with significant year-over-year increases in both Cell Therapy (Yescarta and Tecartus) and Trodelvy sales, reflecting continued demand and successful market penetration. However, sales of Veklury, the company's COVID-19 treatment, declined substantially due to decreased COVID-19 hospitalizations and the availability of alternative treatments. The company also addressed a significant legal settlement related to HIV antitrust litigation, paying $525 million in the second half of the year, which impacted operating expenses.

Gilead Sciences, Inc. (GILD) reported revenues of $6.60 billion for the third quarter of 2023, a 5% increase year-over-year, driven by growth in HIV and Oncology segments. However, net income attributable to Gilead saw a significant decrease of 9% to $1.045 billion, or $0.83 per diluted share. This decline was primarily influenced by a $525 million litigation accrual for settlements related to HIV antitrust litigation, coupled with higher operating costs and tax expenses. For the first six months of 2023, revenues grew 1% to $12.95 billion, while net income more than doubled to $2.06 billion, largely due to the absence of a significant $2.7 billion IPR&D impairment charge recognized in the prior year's comparable period. The company's strategic focus continues to be on advancing innovative medicines for life-threatening diseases. Acquisitions in the oncology space, such as XinThera and Tmunity, alongside collaborations like Arcellx, highlight Gilead's commitment to expanding its pipeline. Despite a challenging legal environment and increased R&D spending, Gilead's core HIV franchise remains robust, and its cell therapy and oncology products are demonstrating strong growth.

Gilead Sciences, Inc. reported total revenues of $6.35 billion for the first quarter of 2023, a 4% decrease year-over-year, primarily due to lower sales of Veklury (remdesivir). However, the company saw strong growth in its oncology portfolio, with significant increases in Cell Therapy (up 64%) and Trodelvy (up 52%), driven by expanded adoption and new indications. HIV product sales also increased by 13%, indicating continued strength in this core franchise, bolstered by Biktarvy and Descovy for PrEP. Net income attributable to Gilead significantly improved to $1.01 billion, or $0.80 per diluted share, compared to $19 million, or $0.02 per diluted share, in the prior year. This substantial increase was largely driven by the absence of a $2.7 billion in-process research and development impairment charge recorded in Q1 2022. Gilead also made strategic investments, including the acquisition of Tmunity Therapeutics and a collaboration with Arcellx, signaling a continued focus on expanding its oncology pipeline. The company maintained a healthy operating cash flow of $1.74 billion.

Gilead Sciences, Inc. reported total revenues of $7.04 billion for the third quarter of 2022, a 5% decrease from the prior year's $7.42 billion. This decline was primarily driven by a significant drop in Veklury sales, down 52%, as COVID-19 hospitalizations decreased. However, growth in HIV products, cell therapy, and Trodelvy partially offset this decline. Net income attributable to Gilead stockholders was $1.79 billion, or $1.42 per diluted share, compared to $2.59 billion, or $2.05 per diluted share, in the same period last year. The decrease in net income was largely due to a $389 million charge related to the acquisition of MiroBio and a substantial $2.7 billion impairment charge on acquired in-process R&D assets recognized in the second quarter related to Trodelvy. Despite these charges, Gilead continues to invest in R&D and returned capital to shareholders through share repurchases and dividends.

Gilead Sciences, Inc. (GILD) reported its second-quarter 2022 financial results, showing a slight increase in total revenues to $6.26 billion, up 1% year-over-year. This growth was primarily driven by strong performance in its HIV, Cell Therapy, and Trodelvy segments, which offset declines in Veklury and Hepatitis C virus (HCV) sales. However, net income attributable to Gilead decreased significantly by 25% to $1.14 billion, resulting in diluted earnings per share of $0.91. This decline was mainly due to a substantial $2.7 billion in-process research and development (IPR&D) impairment charge recorded in the first quarter related to Trodelvy, and an upfront payment for the Dragonfly collaboration. The company's balance sheet remains robust, with total assets of $62.87 billion as of June 30, 2022. While cash and cash equivalents decreased to $4.74 billion, Gilead generated positive operating cash flow of $3.64 billion for the first six months of the year. The company also continues to actively manage its capital structure, repaying debt and returning capital to shareholders through dividends and share repurchases. Gilead also announced a pending acquisition of MiroBio Ltd. for $405 million, signaling continued investment in pipeline expansion.

Gilead Sciences reported revenues of $6.59 billion for the first quarter of 2022, a 3% increase year-over-year. This growth was primarily driven by strong performance in HIV products, particularly Biktarvy, continued uptake of cell therapy products and Trodelvy, and increased sales of Veklury. However, net income attributable to Gilead stockholders significantly declined by 99% to $19 million ($0.02 per diluted share) compared to $1.7 billion ($1.37 per diluted share) in the prior year. The substantial decrease in net income was largely due to a $2.7 billion impairment charge related to in-process research and development assets acquired for Trodelvy. Despite this non-recurring charge, the company's operational performance showed resilience with revenue growth across key therapeutic areas. Gilead also continued its capital return strategy, repurchasing shares and paying dividends, while maintaining a strong cash position and managing its debt.

Gilead Sciences reported a strong third quarter of 2021, with total revenues increasing by 13% year-over-year to $7.4 billion. This growth was primarily driven by a significant surge in Veklury (remdesivir) sales, boosted by the ongoing COVID-19 pandemic, as well as continued growth in Biktarvy and the uptake of newer products like Trodelvy and cell therapies. Despite the strong revenue performance, investors should note the expected decline in HIV product sales due to generic competition following the loss of exclusivity for Truvada and Atripla. The company also reported a substantial increase in net income attributable to Gilead, largely due to lower acquired in-process R&D expenses compared to the prior year, which was impacted by significant acquisition-related charges. The balance sheet shows a decrease in cash and cash equivalents, reflecting debt repayments, dividend payments, and stock repurchases, alongside strategic investments.

Gilead Sciences, Inc. reported robust financial results for the second quarter and first half of 2021, demonstrating significant revenue growth and a return to profitability compared to the prior year. Total revenues increased by 21% year-over-year for the quarter and 18% for the first half, primarily driven by strong sales of Veklury (remdesivir) for COVID-19 treatment, alongside continued growth in Biktarvy for HIV, and solid performance in Cell Therapy and other product categories. The company has shown a substantial improvement in profitability, with net income attributable to Gilead reaching $1.5 billion for the quarter and $3.3 billion for the first half, a significant turnaround from the net losses reported in the same periods of 2020. This improvement is largely due to strong revenue growth and the absence of significant one-time charges, such as the large acquired IPR&D expense recorded in Q2 2020. Gilead continues to manage its debt effectively and maintain a strong liquidity position, supported by consistent operating cash flow.

Gilead Sciences, Inc. (GILD) reported solid financial results for the first quarter of 2021, with total revenues increasing by 16% year-over-year to $6.4 billion. This growth was primarily driven by significant sales of Veklury (remdesivir), its treatment for COVID-19, which generated $1.5 billion in revenue, a substantial increase from the prior year's first quarter where Veklury sales were not yet recognized. Net income attributable to Gilead also saw a healthy increase of 11% to $1.7 billion, resulting in diluted earnings per share of $1.37, up 12% from the prior year. The company's strategic acquisitions, including Immunomedics and MYR, are beginning to contribute to revenue, particularly in the oncology (Trodelvy) and viral disease (Hepcludex) segments. However, traditional HIV product sales experienced a 12% decline, primarily due to generic competition following the loss of exclusivity for Truvada and Atripla. Investors should monitor the ongoing impact of Veklury sales volatility, the continued integration of acquired assets, and the performance of key therapeutic areas in light of competitive pressures.

Gilead Sciences, Inc. reported robust revenue growth in the third quarter of 2020, driven by strong performance in its HIV and cell therapy segments, as well as significant contributions from Veklury (remdesivir) for COVID-19 treatment. Total revenues increased by 17% year-over-year to $6.6 billion. The company swung to a net income of $360 million ($0.29 per diluted share) from a net loss in the prior-year period, largely influenced by substantial acquired in-process research and development (IPR&D) expenses and a significant unrealized loss on equity investments. Gilead also announced its agreement to acquire Immunomedics for approximately $21 billion, a strategic move to bolster its oncology pipeline, which closed shortly after the quarter's end. Despite challenges posed by the COVID-19 pandemic on certain product lines like HCV, Gilead demonstrated resilience and strategic execution. The company's ability to scale Veklury production and distribution globally highlights its operational capabilities during a critical public health crisis. Key investments in its oncology portfolio and ongoing pipeline development signal a strategic focus on long-term growth.

Gilead Sciences, Inc. reported a net loss of $3.3 billion for the second quarter of 2020, a significant shift from a net income of $1.9 billion in the prior year period. This loss was primarily driven by a $4.5 billion charge for acquired in-process research and development related to the acquisition of Forty Seven, Inc. Total revenues decreased by 10% year-over-year to $5.1 billion, largely due to lower sales of Hepatitis C (HCV) products impacted by the COVID-19 pandemic, as well as a decline in sales for Letairis and Ranexa following generic entries. Despite the quarterly loss, the company highlighted ongoing progress in its strategic initiatives, including advancing its immuno-oncology pipeline through acquisitions and collaborations such as Forty Seven, Arcus Biosciences, Pionyr Immunotherapeutics, and Tizona Therapeutics. Gilead also continued to focus on remdesivir (Veklury) for COVID-19, securing regulatory approvals and authorizations in key markets and expanding manufacturing capacity. While the pandemic impacted sales volumes across several therapeutic areas, the core HIV franchise showed underlying demand growth, with strong uptake of Biktarvy and Descovy for PrEP.

Gilead Sciences, Inc. reported total revenues of $5.55 billion for the first quarter of 2020, a 5% increase year-over-year, driven primarily by robust growth in HIV product sales. Despite a 44% decline in Atripla sales and a 33% decrease in Truvada sales, the company saw significant increases in Biktarvy (113%) and Descovy (34%). However, net income attributable to Gilead decreased by 22% to $1.55 billion, or $1.22 per diluted share, from $1.98 billion, or $1.54 per diluted share, in the prior year. This decline was largely attributed to unfavorable changes in the fair value of equity investments, notably its investment in Galapagos NV. The company also highlighted its rapid response to the COVID-19 pandemic, particularly the advancement of remdesivir as a potential treatment. Remdesivir received Emergency Use Authorization (EUA) from the FDA in May 2020, and Gilead is scaling up manufacturing significantly. Despite the pandemic's potential impact on healthcare access and patient starts, especially for HIV and HCV treatments, Gilead anticipates continued investment in remdesivir and other pipeline developments, including the acquisition of Forty Seven, Inc. for $4.9 billion in April 2020 to bolster its oncology pipeline.

Gilead Sciences, Inc. reported revenues of $5,604 million for the third quarter of 2019, a slight increase from $5,596 million in the prior year period, driven by higher product sales, particularly in HIV. However, the company posted a net loss of $1.2 billion, or $0.92 per share, for the quarter. This loss was primarily attributable to a significant $3.92 billion up-front payment related to the Option, License and Collaboration Agreement with Galapagos NV, which also included an equity investment of $1.13 billion. Despite the quarterly loss, Gilead's cash position remains robust, with $25.1 billion in cash, cash equivalents, and marketable debt securities as of September 30, 2019. The company's HIV product sales showed strong growth, increasing by 13% year-over-year, largely due to the uptake of Biktarvy. Conversely, HCV product sales continued to decline, down 25%, impacted by increased competition and pricing pressures. R&D expenses saw a substantial increase due to the Galapagos collaboration, while SG&A expenses rose moderately to support international expansion. Investors should note the ongoing litigation related to key products and the company's dependence on HIV and HCV revenues, alongside efforts to diversify through pipeline development and strategic partnerships.

Gilead Sciences, Inc. (GILD) reported its second-quarter 2019 financial results, demonstrating steady performance with a 1% increase in total revenues to $5.7 billion, driven by growth in HIV product sales. Despite a decline in Hepatitis C (HCV) revenues, the company's strategic focus on its core HIV portfolio, particularly with the strong uptake of Biktarvy, continues to be a key revenue driver. Operationally, Gilead saw a decrease in Cost of Goods Sold, leading to an improved product gross margin of 82%. While R&D expenses saw a slight dip year-over-year for the quarter, they increased for the six-month period, reflecting ongoing investments in cell therapy programs. SG&A expenses increased due to promotional activities and international expansion. Net income attributable to Gilead saw a rise to $1.9 billion ($1.47 diluted EPS) for the quarter, reflecting improved operational performance. The company maintained a strong liquidity position with over $30 billion in cash, cash equivalents, and marketable debt securities as of June 30, 2019.

Gilead Sciences, Inc. reported solid first-quarter 2019 results, with total revenues increasing by 4% year-over-year to $5.3 billion. This growth was primarily driven by a 14% increase in HIV product sales, reaching $3.6 billion, largely due to the strong uptake of Biktarvy. While HIV remains the dominant revenue driver, Hepatitis C (HCV) product sales saw a 24% decline to $790 million, attributed to competitive pressures and declining patient starts. The company's financial position remains strong, with $30.1 billion in cash, cash equivalents, and marketable debt securities as of March 31, 2019. Despite generating $1.4 billion in operating cash flow, the company utilized cash for debt repayment, dividends, and significant share repurchases totaling $834 million. Research and development expenses increased by 13%, partly due to collaboration expenses and investments in cell therapy. Investors should note ongoing legal proceedings related to key products and the continued importance of pipeline development to offset declining HCV sales and maintain growth.

Gilead Sciences, Inc. (GILD) reported third quarter and year-to-date results for 2018. Total revenues for the third quarter of 2018 were $5.6 billion, a decrease from $6.5 billion in the prior year's quarter, driven by a 15% decline in product sales. For the nine-month period, total revenues decreased by 19% to $16.3 billion, also primarily due to lower product sales. This decline is largely attributable to a significant decrease in Hepatitis C (HCV) product sales, which fell 59% year-over-year in the third quarter and 61% year-over-year for the nine-month period. The company attributes this to increased competition. On a positive note, HIV product sales showed resilience, increasing by 12% in the third quarter and 10% for the nine-month period, driven by strong uptake of newer treatments like Descovy, Genvoya, Odefsey, and the newly launched Biktarvy. Despite the revenue challenges in HCV, Gilead maintained a strong financial position with $30.8 billion in cash, cash equivalents, and marketable securities as of September 30, 2018. The company generated $6.1 billion in operating cash flow for the nine months ended September 30, 2018, but used significant cash for debt repayments ($1.8 billion senior unsecured notes, $4.5 billion term loans) and stock repurchases ($1.9 billion), leading to a net decrease in cash. Research and development expenses increased notably by 19% for both periods, driven by costs associated with the Kite Pharma acquisition, while Selling, General, and Administrative expenses also saw increases. The company continues to invest in its pipeline and integrate the Kite acquisition, positioning for future growth in oncology and other therapeutic areas.

Gilead Sciences (GILD) reported a significant decrease in total revenues for the second quarter of 2018, down 21% year-over-year to $5.6 billion, primarily driven by a 21% decline in product sales to $5.5 billion. This was largely attributable to a substantial 65% drop in Hepatitis C (HCV) product sales due to increased competition, while HIV product sales saw a healthy 13% increase, driven by the uptake of Descovy-based products. Despite the revenue decline, Gilead demonstrated strong operational cash flow generation of $3.8 billion for the first six months of the year. The company also continued to invest in its future, with Research and Development (R&D) expenses increasing by 38% in the quarter, fueled by collaboration payments and acquisition-related costs, notably for the Kite Pharma acquisition. Management expresses confidence in existing capital resources to meet future needs, supported by substantial cash reserves. However, investors should note the ongoing legal challenges and patent litigations, particularly concerning its key HCV products, which represent a notable risk factor.

Gilead Sciences reported first-quarter 2018 revenues of $5.1 billion, a decrease of 22% year-over-year, primarily driven by a significant decline in Hepatitis C (HCV) product sales. While HIV and Hepatitis B (HBV) product sales saw a modest increase due to the strong performance of Descovy-based regimens, the sharp drop in HCV sales, particularly Harvoni and Sovaldi, overshadowed this growth. The company is actively managing a complex legal landscape, with ongoing patent disputes and government investigations presenting potential risks. Despite the revenue decline, Gilead generated substantial operating cash flow of $2.3 billion. The company also repaid $4.5 billion in term loans and continued its share repurchase program, demonstrating a commitment to returning capital to shareholders. Management acknowledges the expected decline in HCV sales for the full year 2018 due to increased competition and is focusing on the growth of its HIV franchise, particularly with the recent launch of Biktarvy.

Gilead Sciences, Inc. reported total revenues of $6.51 billion for the third quarter of 2017, a decrease of 13% from $7.50 billion in the prior year period, primarily driven by lower product sales in its antiviral segment, particularly Hepatitis C (HCV) treatments. While HIV and Hepatitis B (HBV) product sales showed resilience and growth driven by newer TAF-based regimens, the HCV franchise, including blockbuster drugs like Harvoni and Sovaldi, experienced a significant decline. This downturn is attributed to a rapid decrease in patient starts following widespread treatment and cures, coupled with increasing competition. The company also highlighted its significant acquisition of Kite Pharma for approximately $11.2 billion, aiming to establish a strong position in the rapidly growing cell therapy market with the approval of Yescarta. Despite revenue pressures in the core antiviral business, Gilead maintained a strong cash position and continued its share repurchase program.

Gilead Sciences, Inc. (GILD) reported financial results for the second quarter ended June 30, 2017. Total revenues decreased by 8% year-over-year to $7.1 billion, primarily driven by a decline in antiviral product sales, particularly within the Hepatitis C (HCV) segment. While HIV and Hepatitis B (HBV) product sales showed growth, largely due to the uptake of newer tenofovir alafenamide (TAF)-based treatments, the decrease in HCV sales, attributed to a maturing market and increased competition, significantly impacted overall revenue. Net income attributable to Gilead for the quarter was $3.1 billion, or $2.33 per diluted share, a decrease from the prior year's $3.5 billion, or $2.58 per diluted share. This decline reflects the lower revenues, partially offset by reduced operating expenses, especially in Research & Development, and share repurchases which favorably impacted earnings per share. The company maintained a strong liquidity position with substantial cash, cash equivalents, and marketable securities totaling $36.6 billion.

Gilead Sciences, Inc. reported total revenues of $6.5 billion for the first quarter of 2017, a decrease of 17% compared to $7.8 billion in the same period of 2016. This decline was primarily driven by a significant drop in Hepatitis C (HCV) product sales, which fell by 19% year-over-year to $2.6 billion, mainly due to lower sales of Harvoni and Sovaldi. However, sales of HIV and Hepatitis B (HBV) products increased by 13% to $3.3 billion, bolstered by the uptake of TAF-based regimens like Genvoya and Descovy. Net income attributable to Gilead for the quarter was $2.7 billion, or $2.05 per diluted share, down from $3.6 billion, or $2.53 per diluted share, in Q1 2016. Despite the revenue challenges in HCV, the company maintained a strong cash position with $34.0 billion in cash, cash equivalents, and marketable securities as of March 31, 2017. Gilead continued its share repurchase program, buying back $565 million worth of stock in the quarter.

Gilead Sciences, Inc. (GILD) reported revenues of $7.5 billion for the third quarter of 2016, a decrease of 10% year-over-year, primarily driven by lower product sales, which fell to $7.4 billion from $8.2 billion in the prior year period. This decline was largely attributed to decreased sales of Hepatitis C (HCV) products like Harvoni and Sovaldi, partially offset by the new launch of Epclusa. Conversely, sales of HIV and other antiviral products saw a notable increase, driven by the uptake of newer tenofovir alafenamide (TAF)-based products such as Genvoya, Descovy, and Odefsey. Research and development (R&D) expenses increased significantly to $1.1 billion from $743 million in the prior year's quarter, mainly due to ongoing clinical studies and a milestone expense related to an acquisition. Net income attributable to Gilead decreased to $3.3 billion ($2.49 per diluted share) from $4.6 billion ($3.06 per diluted share) in the same quarter last year, impacted by lower sales and higher R&D costs. Despite the revenue decline, Gilead maintained a strong cash position, with $31.6 billion in cash, cash equivalents, and marketable securities as of September 30, 2016, and continued its aggressive share repurchase program.

Gilead Sciences, Inc. reported total revenues of $7.8 billion for the second quarter of 2016, a 6% decrease year-over-year, primarily driven by a 6% decline in product sales to $7.7 billion. This decrease was largely attributed to lower sales of Hepatitis C (HCV) treatments, particularly Harvoni, which saw a 29% drop in sales for the quarter. Despite the decline in HCV revenue, Gilead demonstrated growth in its HIV franchise, with sales of tenofovir alafenamide (TAF)-based products like Genvoya, Descovy, and Odefsey showing strong uptake. Research and development expenses significantly increased to $1.5 billion due to strategic acquisitions and pipeline progression, while net income attributable to Gilead was $3.5 billion, or $2.58 per diluted share, a decrease from the prior year's $4.5 billion, or $2.92 per diluted share. The company also continued its aggressive share repurchase program, demonstrating a commitment to returning capital to shareholders.

Gilead Sciences, Inc. reported first-quarter 2016 results showing total revenues of $7.8 billion, a modest increase from the prior year, primarily driven by growth in antiviral products. While overall revenue grew, net income attributable to Gilead declined to $3.6 billion, or $2.53 per diluted share, from $4.3 billion, or $2.76 per diluted share, in the first quarter of 2015. This decline was attributed to increased costs in cost of goods sold (including a significant litigation charge), research and development, and selling, general, and administrative expenses. The company's balance sheet showed a decrease in cash, cash equivalents, and marketable securities to $21.3 billion from $26.2 billion at the end of 2015, largely due to substantial share repurchases and strategic investments. Gilead continues to face significant litigation and regulatory scrutiny, particularly concerning its hepatitis C products.

Gilead Sciences, Inc. (GILD) reported strong financial results for the third quarter and first nine months of 2015, driven by significant growth in its Hepatitis C (HCV) products, Harvoni and Sovaldi. Total revenues for the third quarter of 2015 reached $8.3 billion, a substantial increase from $6.0 billion in the prior year's quarter. Net income also saw a significant jump, reaching $4.6 billion ($3.06 per diluted share) in Q3 2015, up from $2.7 billion ($1.67 per diluted share) in Q3 2014. The company's balance sheet reflects robust liquidity, with cash, cash equivalents, and marketable securities totaling $25.1 billion as of September 30, 2015. Gilead also actively managed its capital structure, issuing $10 billion in senior unsecured notes and repurchasing approximately $7.0 billion of its common stock during the nine-month period. The company initiated a quarterly dividend program, demonstrating a commitment to returning value to shareholders.

Gilead Sciences, Inc. reported strong financial results for the quarter ending June 30, 2015, driven by robust sales of its Hepatitis C (HCV) treatments, Harvoni and Sovaldi. Total revenues saw a significant increase of 27% year-over-year, reaching $8.2 billion, with product sales leading the growth. The company's net income also saw a substantial rise, indicating effective product performance and market penetration. Despite increased research and development (R&D) and selling, general, and administrative (SG&A) expenses, Gilead maintained healthy profit margins. The company also demonstrated strong cash flow generation from operations and managed its capital effectively, evidenced by substantial cash reserves and ongoing share repurchase programs. Gilead also initiated its first quarterly cash dividend, signaling confidence in its financial stability and commitment to returning value to shareholders.

Gilead Sciences, Inc. (GILD) reported a strong first quarter for 2015, demonstrating significant revenue growth driven by its highly successful Hepatitis C (HCV) franchise, particularly Harvoni and Sovaldi. Total revenues reached $7.6 billion, a substantial increase from $5.0 billion in the prior year's quarter, with HCV product sales alone contributing $4.6 billion. The company also showed robust performance in its HIV product sales, which grew by 9% year-over-year, bolstered by single-tablet regimens like Stribild and Complera/Eviplera. This strong top-line performance translated into a significant jump in net income to $4.3 billion ($2.76 per diluted share) from $2.2 billion ($1.33 per diluted share) in the first quarter of 2014. Financially, Gilead maintained a strong liquidity position with over $14.5 billion in cash, cash equivalents, and marketable securities. The company actively returned capital to shareholders, completing a $3.0 billion stock repurchase program and announcing a new $15.0 billion program, alongside the initiation of its first quarterly dividend. However, investors should note ongoing legal proceedings and potential competition, particularly in the HCV market, as key areas to monitor.

Gilead Sciences, Inc. (GILD) reported robust financial results for the third quarter of 2014, driven significantly by the strong performance of its antiviral products, particularly Sovaldi. Total revenues surged to $6.04 billion, a substantial increase from $2.78 billion in the prior year's quarter. This growth was primarily fueled by Sovaldi sales, which reached $2.80 billion, and continued strength in their HIV single tablet regimens like Stribild and Complera/Eviplera. Despite increased Research and Development (R&D) and Selling, General & Administrative (SG&A) expenses, partly due to a one-time catch-up charge for the Branded Prescription Drug Fee, net income attributable to Gilead rose to $2.73 billion, or $1.67 per diluted share. The company also strengthened its balance sheet, ending the quarter with $7.69 billion in cash, cash equivalents, and marketable securities. Gilead's pipeline advanced with the approval of Harvoni for Hepatitis C, further solidifying its market position. Investors should note the significant legal proceedings related to sofosbuvir patents and ongoing generic competition as key areas to monitor.

Gilead Sciences, Inc. reported a significant surge in revenue for the second quarter of 2014, primarily driven by the successful launch of its Hepatitis C drug, Sovaldi. Total revenues reached $6.53 billion, a substantial increase from $2.77 billion in the same period of the prior year, with Sovaldi alone generating $3.48 billion in sales. This performance led to a net income attributable to Gilead of $3.66 billion, or $2.20 per diluted share, a marked improvement from the previous year's quarter. The company also demonstrated strong cash generation, with cash, cash equivalents, and marketable securities increasing to $9.58 billion. Gilead continued its commitment to returning value to shareholders through significant stock repurchases, authorized a new $5 billion repurchase program, and managed its debt effectively by repaying outstanding balances. Despite increased R&D and SG&A expenses to support its growing business, Gilead's financial health appears robust, positioning it for continued growth and investment in its pipeline.

Gilead Sciences, Inc. reported a significant increase in revenue and net income for the first quarter of 2014, primarily driven by the launch of its new hepatitis C treatment, Sovaldi. Total revenues nearly doubled year-over-year to $5.00 billion, with Sovaldi generating an impressive $2.27 billion in sales in its first full quarter post-launch. This strong performance in the antiviral segment, coupled with continued growth in HIV products like Stribild and Complera/Eviplera, led to a substantial rise in profitability, with net income attributable to Gilead soaring by 208% to $2.23 billion. The company also strengthened its financial position by issuing $4.00 billion in senior unsecured notes and increasing its cash reserves to $6.86 billion. While R&D and SG&A expenses increased to support pipeline progression and market expansion, the overwhelming success of Sovaldi has positioned Gilead for continued growth. Investors should monitor the ongoing patent litigations, particularly concerning sofosbuvir, and the market uptake of new HCV combination therapies.

Gilead Sciences, Inc. reported strong financial performance for the third quarter and first nine months of 2013, with total revenues increasing by 15% and 14% year-over-year, respectively. This growth was primarily driven by a 15% increase in product sales, largely attributable to the antiviral franchise, which saw a 14% rise. The company also highlighted significant revenue growth in its cardiovascular products. Net income increased by 17% year-over-year for the third quarter, reflecting robust sales and effective cost management. Financially, Gilead Sciences maintained a healthy liquidity position with $2.76 billion in cash, cash equivalents, and marketable securities as of September 30, 2013. The company actively managed its debt, repaying a significant portion of its long-term obligations. Key strategic developments include the completion of the YM BioSciences acquisition, aimed at advancing its oncology pipeline with momelotinib. Furthermore, Gilead is progressing with its Hepatitis C (HCV) pipeline, with a New Drug Application (NDA) filed for sofosbuvir and positive outlooks from FDA advisory committees. Investors should note the ongoing patent litigation related to key antiviral products, which presents potential risks, although the company has settled some cases and is actively defending others.

Gilead Sciences, Inc. reported solid financial performance for the second quarter and first half of 2013, demonstrating robust revenue growth driven by its antiviral and cardiovascular product portfolios. Total revenues increased by 15% year-over-year for the quarter to $2.77 billion, with product sales up 14% to $2.66 billion. This growth was primarily fueled by strong demand for HIV treatments like Complera/Eviplera and Stribild, alongside continued strength in established products. The company also saw a significant 31% increase in royalty revenues, notably from Tamiflu. Despite increased investments in Research and Development (R&D) to support its pipeline, particularly in oncology and liver disease, Gilead maintained healthy profitability, with net income attributable to Gilead increasing by 9% to $772.6 million for the quarter. Financially, Gilead maintained a strong liquidity position, with cash, cash equivalents, and marketable securities totaling $2.98 billion as of June 30, 2013. The company successfully managed its debt, repaying a significant portion of its outstanding obligations. A notable event during the period was the completion of the acquisition of YM BioSciences Inc. for $487.6 million, which is expected to bolster its oncology pipeline. Looking ahead, Gilead is advancing its Hepatitis C (HCV) program with the filing of an NDA for sofosbuvir and promising data from its sofosbuvir/ledipasvir combination studies, positioning the company for potential future growth in this critical therapeutic area. Investors should monitor patent litigation developments and the ongoing regulatory review of key pipeline assets.

Gilead Sciences, Inc. reported strong financial performance for the first quarter of 2013, with total revenues increasing 11% year-over-year to $2.53 billion, driven by robust product sales and a significant rise in royalty revenues. Product sales grew 8% to $2.39 billion, primarily fueled by the antiviral franchise and cardiovascular products, despite a slight sequential decline due to inventory adjustments. Net income attributable to Gilead saw a substantial increase of 63% to $722.2 million, resulting in diluted earnings per share of $0.43. This growth was propelled by increased revenues, a significant decrease in Selling, General, and Administrative (SG&A) expenses (largely due to lower stock-based compensation post-acquisition), and a favorable adjustment to the effective tax rate. The company also completed the acquisition of YM BioSciences Inc. for $487.6 million, bolstering its oncology pipeline, and generated a healthy $672.1 million in operating cash flow.

Gilead Sciences, Inc. reported strong financial performance for the nine months ended September 30, 2012. Total revenues grew 15% year-over-year to $7.11 billion, driven by a 15% increase in product sales to $6.89 billion. This growth was primarily fueled by the company's antiviral franchise, with significant contributions from Atripla and Truvada. The company's financial results were significantly impacted by the acquisition of Pharmasset, Inc. for $11.1 billion in January 2012, which added substantial intangible assets. While this acquisition led to increased R&D and interest expenses, Gilead maintained a healthy product gross margin of 74% for the nine-month period. Despite a decrease in net income due to these investments and increased debt, diluted earnings per share remained robust. The company ended the period with $2.65 billion in cash, cash equivalents, and marketable securities, indicating solid liquidity to fund ongoing operations and strategic initiatives.

Gilead Sciences, Inc. (GILD) reported its financial results for the quarter and six months ended June 30, 2012. Total revenues showed a notable increase, up 13% year-over-year for the quarter and 15% for the six-month period, primarily driven by strong product sales in its antiviral franchise. The company's flagship products, Atripla and Truvada, continued to perform well, contributing significantly to revenue growth. However, net income for the quarter saw a slight decrease of 5% compared to the prior year, attributed to increased investments in R&D, particularly in liver disease and oncology, and higher interest expenses related to recent debt issuance. This increase in R&D reflects the company's ongoing commitment to pipeline advancement. The company also significantly drew down its cash reserves, largely due to the substantial $11.1 billion acquisition of Pharmasset in January 2012, which is expected to bolster its Hepatitis C (HCV) franchise with the lead compound GS-7977. Operationally, Gilead is advancing several key initiatives. Truvada received FDA approval for pre-exposure prophylaxis (PrEP) for HIV prevention, a significant development for the company's HIV portfolio. In the HCV space, promising data from Phase 2 and Phase 3 studies for GS-7977 were reported, positioning the company for potential regulatory filings. The company also advanced its oncology pipeline with Phase 3 studies for GS-1101. Despite the increased R&D spending and the significant cash outflow for the Pharmasset acquisition, Gilead's liquidity remains a point of focus, with cash, cash equivalents, and marketable securities decreasing substantially from the end of 2011. Investors should monitor the progress of the HCV pipeline and the integration of Pharmasset.

Gilead Sciences, Inc. (GILD) reported its first-quarter 2012 financial results, showcasing robust revenue growth driven primarily by its antiviral franchise. Total revenues increased by 19% year-over-year to $2.28 billion, with product sales reaching $2.21 billion, up 19% from the prior year. This growth was largely fueled by strong performances from Atripla and Truvada, alongside the launch of Complera/Eviplera. The company also significantly advanced its strategic agenda with the completion of the $11.1 billion acquisition of Pharmasset, Inc., a move expected to bolster its Hepatitis C (HCV) portfolio and accelerate its development of all-oral HCV regimens. While net income saw a decline of 32% to $442 million, this was primarily due to a substantial $193.9 million charge for accelerated stock option vesting related to the Pharmasset acquisition, as well as increased interest expenses from new debt financing. The company continues to invest heavily in research and development, with R&D expenses increasing by 80% to $458.2 million, largely driven by the aforementioned acquisition-related stock compensation and ongoing clinical studies. Selling, General, and Administrative (SG&A) expenses also rose by 50% to $443.1 million, impacted by similar acquisition-related costs and increased pharmaceutical excise taxes. Despite these increased expenses and the significant cash outflow for the Pharmasset acquisition, Gilead's operating cash flow remained strong at $453 million, demonstrating its underlying business resilience.

Gilead Sciences, Inc. reported strong financial performance for the third quarter and first nine months of 2011. Total revenues increased year-over-year, driven by robust sales of its antiviral products, particularly Atripla and Truvada, which together represented a significant portion of total revenue. The company also saw growth in its other therapeutic areas like cardiovascular and respiratory. Gilead announced the U.S. FDA approval of Complera for HIV treatment, further expanding its single-tablet regimen offerings. Significant investments in research and development continued, alongside strategic acquisitions of Arresto Biosciences and Calistoga Pharmaceuticals, bolstering its pipeline in oncology and inflammatory diseases. The company also completed a major stock repurchase program and initiated a new one, demonstrating a commitment to returning capital to shareholders. Financially, Gilead maintained a strong balance sheet with substantial cash, cash equivalents, and marketable securities. Operating cash flow remained healthy, supporting ongoing R&D, acquisitions, and capital returns. While the company faced some challenges, such as decreased royalty revenues from Tamiflu due to declining pandemic planning, and increased SG&A expenses related to acquisitions and the pharmaceutical excise tax, overall performance indicated solid growth and a positive outlook.

Gilead Sciences, Inc. reported strong performance for the second quarter of 2011, with total revenues reaching $2.14 billion, a 11% increase year-over-year. Product sales were the primary driver, up 13% to $2.04 billion, fueled by robust demand for its HIV medications, particularly Atripla and Truvada, which saw 15% and 11% sales growth, respectively. This growth was observed across key geographies, including the United States and Europe, despite some headwinds like austerity measures in Europe and the impact of U.S. healthcare reform. The company also made significant strategic moves, including acquisitions of Arresto Biosciences and Calistoga Pharmaceuticals, bolstering its pipeline in oncology and inflammation. Gilead's financial position remains solid, with a substantial cash and marketable securities balance, and the company continued its share repurchase program. Despite the positive revenue trends, Gilead's cost of goods sold increased by 17% in the quarter, leading to a slight compression in gross margin to 74%. Research and Development (R&D) and Selling, General, and Administrative (SG&A) expenses also saw notable increases of 22% and 23%, respectively, driven by acquisitions, collaborations, and increased headcount. The company's effective tax rate decreased to 24.4% compared to the prior year. Overall, Gilead demonstrated strong operational performance, driven by its core antiviral franchise, while strategically investing in future growth through acquisitions and R&D.

Gilead Sciences, Inc. (GILD) reported its first quarter 2011 financial results, demonstrating continued revenue growth driven by its core antiviral products, Atripla and Truvada. While product sales increased by 4% year-over-year, the company experienced a significant 80% decline in royalty revenues, primarily due to reduced Tamiflu sales. This impact on royalties, despite strong product sales, led to a decrease in net income and diluted earnings per share compared to the prior year's quarter. The company made strategic acquisitions, notably Calistoga Pharmaceuticals, to bolster its pipeline in oncology and inflammation, and also announced a new research collaboration with Yale School of Medicine. Operationally, Gilead strengthened its balance sheet through the issuance of $1 billion in senior unsecured notes and continued its aggressive share repurchase program. Despite a challenging revenue mix shift due to lower royalty income, the company maintains a strong liquidity position and a robust cash flow from operations. Investors should note the ongoing patent litigation concerning key products and the potential impact of healthcare reforms and European austerity measures on future sales and profitability.

Gilead Sciences, Inc. reported robust financial performance for the nine months ended September 30, 2010, demonstrating significant year-over-year growth. Total revenues increased by 19.7% to $5.95 billion, driven primarily by a 17% surge in product sales, reaching $5.46 billion. This growth was largely fueled by strong performances in their antiviral franchise, particularly Atripla and Truvada, which together accounted for over 73% of total product sales in the third quarter. The company also saw a notable increase in cash and cash equivalents, reaching $5.05 billion by the end of the period, supported by strong operating cash flows and proceeds from the issuance of convertible senior notes. While R&D expenses saw a slight decrease, likely due to a reimbursement from a collaboration, overall investment in growth remains evident. Management highlighted advancements in their pipeline, particularly in the HIV and liver disease areas, underscoring a continued commitment to innovation. However, investors should note the impact of U.S. healthcare reform, estimated to reduce net product sales by approximately $200 million in 2010. Additionally, Gilead has undertaken significant stock repurchases and has issued convertible senior notes, demonstrating active capital management. The company's strong financial footing, coupled with a promising pipeline, positions it well for continued growth, though regulatory and market access challenges remain key considerations.

Gilead Sciences, Inc. reported strong financial results for the second quarter and first half of 2010, demonstrating robust revenue growth primarily driven by its antiviral franchise, particularly Atripla and Truvada. Total revenues increased by 15% year-over-year for the quarter to $1.93 billion and 19% for the first half to $4.01 billion. Net income also saw a significant increase, reflecting improved operational efficiency and strong product demand. The company continued to invest in research and development, with key advancements in its HIV and liver disease pipelines. Gilead also announced a new $5.0 billion stock repurchase program, underscoring its commitment to returning value to shareholders and maintaining a strong financial position with substantial cash reserves.

Gilead Sciences, Inc. reported strong financial performance for the first quarter of 2010, driven by robust product sales, particularly in its antiviral and HIV/AIDS portfolio. Total revenues increased significantly year-over-year, bolstered by substantial growth in Atripla and Truvada sales, along with a notable surge in royalty revenues primarily from Tamiflu. The company demonstrated healthy operating income and net income, with solid cash flow generation from operations. While overall financial health appears strong, investors should note the increasing impact of healthcare reform legislation in the U.S., which is projected to reduce product sales. Additionally, the company continues to invest heavily in research and development, leading to increased operating expenses. Despite these factors, Gilead Sciences remains a dominant player in its therapeutic areas, with a strong cash position and ongoing strategic initiatives including share repurchases.

Gilead Sciences, Inc. (GILD) reported robust financial performance for the nine months ended September 30, 2009, demonstrating significant revenue growth driven primarily by its antiviral products, particularly Truvada and Atripla. The company successfully integrated the acquisition of CV Therapeutics, expanding its presence in the cardiovascular therapeutic area and adding significant intangible assets and goodwill. Despite increased operating expenses related to R&D reimbursements, restructuring, and integration costs, Gilead maintained strong profitability and generated substantial operating cash flow. The company's liquidity remains solid, supported by substantial cash and marketable securities, and it continues to execute its share repurchase program.

Gilead Sciences, Inc. (GILD) reported strong financial performance for the quarter and six months ending June 30, 2009, driven by significant growth in its antiviral product sales, particularly Truvada and Atripla. Total revenues increased substantially year-over-year, reflecting robust demand for its HIV treatments. The company completed the acquisition of CV Therapeutics in April 2009, which is expected to expand its presence in the cardiovascular therapeutic area and contributed $951.2 million in intangible assets related to marketed products and $180.1 million to in-process R&D. Despite increased operating expenses related to the acquisition and restructuring efforts, Gilead maintained healthy profitability and generated strong operating cash flows. The company's balance sheet shows a solid cash position, although it decreased due to the CV Therapeutics acquisition and stock repurchases. Gilead continues to focus on its core antiviral business while strategically investing in new therapeutic areas through acquisitions and collaborations. The company is also actively managing its capital structure, including ongoing stock repurchase programs and prudent management of its credit facility. Investors should note the significant contribution of HIV products to overall revenue and the company's ongoing efforts to expand its product portfolio and R&D pipeline.